Evidence map›Paper›PMID 40301034›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Impact of the FIB4 Index on Pre-sarcopenia in Patients with Metabolic-dysfunction Associated Steatotic Liver Disease.

Hiroki Nishikawa, Tomohiro Nishikawa, Akira Fukuda, Kosuke Ushiro, Masahiro Matsui, Saori Onishi, Soo Ki Kim, Akira Asai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroki NishikawaSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Japan.
Tomohiro NishikawaSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Japan.
Akira FukudaOsaka Medical and Pharmaceutical University Health Science Clinic, Japan.
Kosuke UshiroSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Japan.
Masahiro MatsuiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Japan.
Saori OnishiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Japan.
Soo Ki KimDepartment of Gastroenterology, Kobe Asahi Hospital, Japan.
Akira AsaiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To compare the effect of the FIB4 index on skeletal muscle mass (SMM) loss (i.e., pre-sarcopenia) with that of three other liver fibrosis markers [FIB3 index, aminotransferase to platelet ratio index (APRI), and platelet count] or sarcopenia-related factors such as age and body mass index (BMI) in patients with metabolic dysfunction associated with steatotic liver disease (MASLD, 2,093 men and 1,280 women; median age, 55 years). Methods An SMM decrease was defined as a fat-free index, as tested by a bioelectrical impedance analysis, <18 kg/m

Indexed as

Fatty LiverSarcopeniaAdultAgedBiomarkersBody Mass IndexFemaleHumansLiver CirrhosisMaleMiddle AgedMuscle, SkeletalPlatelet CountBiomarkersBMIFIB4 indexMASLDpredictionpre-sarcopenia

Identifiers

PMID40301034
PMCPMC12659950

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.